The mission of the Translational Therapy Shared Resource (TTSR) is to provide state-of-the-art translational research support services to Masonic Cancer Center (MCC) members to facilitate the monitoring of clinical trials and the development of novel GMP-grade cellular and immune-based therapies. These services are essential to the mission of the MCC because transitioning sophisticated laboratory assays and the manufacturing of biotherapeutic products to the clinic can be difficult and often represents a significant hurdle in translating laboratory studies to patient care. TTSR works directly with members of the scientific programs at the preclinical, clinical, and laboratory levels, with the goal of developing clinical trials to test novel therapies. The TTSR is led by Dr. Martin Felices, PhD, and Dr. John Wagner, MD, with support from Drs. Julie Curtsinger, PhD; David McKenna, MD; and their personnel. It has 2 major components, the Translational Therapy Laboratory (TTL) and Molecular and Cellular Therapeutics (MCT). The TTL provides immune monitoring and biorepository management; it is the central laboratory that receives and processes research blood samples from patients enrolled in clinical trials. MCT is a cGMP-compliant production facility capable of generating GMP-grade cellular and molecular products. The 2 components synergize to help translate promising new therapies into the clinic and to assess biologic outcomes once in patients. The resource has undergone the following changes since the 2013 renewal: ? David McKenna was awarded an NHLBI grant to assist with Production Assistance for Cellular Therapies (PACT). This assists with MCT operational funding. ? Our clinical partner, Fairview, increased its investment in TTSR, highlighting their continued commitment to the Resource. This investment is critical for maintaining TTSR personnel and operations going forward. ? The number of TTL-supported studies has gone up 40% since the last CCSG competing renewal application, resulting in an uptick in the number of clinical samples being processed and managed by this component of the core. ? TTL expanded its biorepository capabilities and now supports a number of solid-tumor studies with processing and storage. ? With the departure of Michael Verneris, Martin Felices assumed the role of Co-Director in 2016. Dr. Felices is an Assistant Professor of Medicine who is well versed in basic and translational immunology and has worked extensively with TTL, first as a researcher and later as part of the core leadership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859364
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Mondragon-Gonzalez, Ricardo; Perlingeiro, Rita C R (2018) Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery. Dis Model Mech 11:
Kim, J-H; Frantz, A M; Sarver, A L et al. (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16:E176-E184
Jin, Jin; Zhang, Lin; Leng, Ethan et al. (2018) Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med 37:3214-3229
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :

Showing the most recent 10 out of 1013 publications